Gastroenterology

Explore safer IBS treatment choices for primary care: lifestyle steps and newer diarrhea/constipation meds beyond antidepressants and opioids.

Experts weigh antidepressants for IBS: small but serious mortality risk, while FDA-approved IBS drugs show stronger trials and long-term safety.

Study of 669 083 patients links antidepressants and some antidiarrheals to higher mortality in IBS, raising prescribing concerns.

Survey shows GI stigma makes Americans dismiss symptoms, delaying diagnosis and driving costs—why primary care conversations matter.

Data show 44-week durable clinical remission in ulcerative colitis and endoscopic response in Crohn disease with duvakitug, a TL1A-targeting monoclonal antibody now in phase 3 trials.

Sebela Pharmaceuticals seeks FDA approval for tegoprazan, a new treatment for GERD, targeting heartburn, erosive esophagitis, and maintenance healing.

Your daily dose of the clinical news you may have missed.

The FDA approves a single monthly injection of mirikizumab-mrkz for ulcerative colitis, enhancing patient convenience and addressing bowel urgency effectively.

The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.

One in ten adults report NCGWS, frequently coexisting with IBS, anxiety, or depression, suggesting a central role for the gut-brain axis in pathophysiology.

FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.

Your daily dose of the clinical news you may have missed.

A family medicine physician details how to differentiate upper airway cough syndrome from asthma and GERD using clinical history and associated symptoms.

FDA approves guselkumab as the first fully subcutaneous IL-23 inhibitor for ulcerative colitis, showing significant clinical benefits in trials.

For initiating colorectal cancer screening in average-risk young adults, a default mailed outreach strategy outperformed 3 active choice options in a randomized study.

Using FMT over standard-of-care therapy may significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.

Your daily dose of the clinical news you may have missed.

DDW 2025. Colonoscopic delivery of fecal therapy prevented recurrent C. diff infection in 95% of participants for 8 weeks, with mild GI adverse events reported by <10%.

Upadacitinib shows promising real-world effectiveness for managing moderate-to-severe Crohn disease, even in patients with prior treatment exposure.

Your daily dose of the clinical news you may have missed.

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.

The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

Researchers at Phoenix Children’s Hospital conducted one of the largest real-world clinical evaluations of the esophageal string test in children.

Your daily dose of the clinical news you may have missed.